The Craneware Group Prepares Hospitals for 340B Rebate Model
Recently, The Craneware Group gathered leaders from 25 major health systems to discuss readiness for the approved 340B Rebate Model Pilot Program. With the formal acceptance of several manufacturers' rebate plans, hospitals are entering a pivotal 60-day preparation period that will lead to the program's launch.
HRSA Approval and Impact on Hospitals
The Health Resources and Services Administration (HRSA) has given the green light to eight manufacturers to participate in this initiative, including renowned companies like Bristol Myers Squibb and AstraZeneca. This significant milestone positions hospitals to take full advantage of the upcoming rebate model set to begin January 1, 2026.
Understanding the 340B Rebate Model
The 340B Rebate Model is designed to provide financial benefits to hospitals serving vulnerable patient populations. The Craneware Group believes that the recent announcement marks a crucial transition to real-world application, where entities can start to capture and benefit from available rebates.
Collaboration for Success
During the forum held at their headquarters, The Craneware Group showcased how its platform, Trisus®, integrates the new 340B rebate functionalities. This demonstration was critical in informing hospital leaders about operational changes and readiness strategies that fall under HRSA's pilot framework.
Key Operational Changes Under HRSA’s Pilot
Several significant operational themes were clarified during discussions, such as:
- Discount Priority: 340B rebates will take precedence over Medicare Fair Price during the same dispensing instance.
- Continuity: The majority of current 340B processes will remain intact, with only specific high-cost National Drug Codes (NDCs) affected by the pilot.
- Payment Timelines: The expectation is set for rebate processing benchmarks, namely 10 days for 340B and 14 days for MFP post-request.
- Integration: Claims for pilot NDCs will be seamlessly processed through Beacon, with The Craneware Group facilitating workflows within the Trisus® platform to maintain transparency and efficiency.
Empowering Hospitals with Trisus®
The Craneware Group assures its clients that participation in the 340B Pilot can proceed without the need to contract new vendors or acquire additional software. The company is committed to making this transition easy for its users, allowing them streamlined access to essential 340B rebate workflows right within their existing operational environment.
Maximizing Opportunities with Trisus®
Lidia Rodriguez-Hupp, Chief Customer Officer, emphasizes that there is no need for clients to pursue separate compliance measures or benefits. Their trusted Trisus® platform already covers charge capture, compliance, and financial analytics, simplifying the necessary adjustments for the rebate model.
Next Steps for Healthcare Entities
As healthcare entities prepare for the upcoming changes, they can schedule live demonstrations to familiarize themselves with the new rebate functionalities. The Craneware Group also offers webinars focused on these adaptations, providing additional support and guidance for all stakeholders involved.
Frequently Asked Questions
What is the 340B Rebate Model?
The 340B Rebate Model allows hospitals serving low-income patients to obtain rebates on drugs purchased through the 340B program.
What companies are involved in the 340B Rebate Model Pilot?
Eight manufacturers including Bristol Myers Squibb and AstraZeneca have been approved to participate in the pilot.
When does the 340B Rebate Program officially start?
The program is set to begin on January 1, 2026, following a 60-day readiness preparation period.
How does Trisus® support hospitals in this process?
Trisus® integrates important rebate workflows, allowing hospitals to manage their rebates without needing new software or vendor partnerships.
What other services does The Craneware Group provide?
The Craneware Group offers cloud-based solutions for charge capture, compliance, and analytics, helping hospitals improve their financial sustainability.
